On November 4, 2022, the Beijing Stock Exchange released the list of constituent stocks for the Beijing Stock Exchange 50 Index (hereinafter referred to as the “Beijing Stock Exchange 50”). Our company was selected as a constituent stock and ranks among the top five largest-weighted stocks.

The “North Exchange 50” is the first index launched by the Beijing Stock Exchange. It selects the top 50 securities based on market capitalization and liquidity, aiming to reflect the overall performance of the 50 most representative and promising securities in the Beijing Stock Exchange market, thereby helping investors gain a better understanding of the market’s overall operational status. The constituent stocks in the inaugural edition account for 71% of the total market capitalization, and their combined share of operating revenue, net profit, and R&D expenditure all exceed 65%, covering 16 specific sub-sectors.

The index serves as a “barometer” of the market. The North Exchange 50 Index provides an important reference for all market participants to track, observe, and make investment decisions, enabling investors to gain a better understanding of the overall performance of securities listed on the Beijing Stock Exchange and meeting the demand for indexed investing. At the same time, the launch of the North Exchange 50 Index conveys a positive expectation that the Beijing Stock Exchange will continue to advance reform and innovation, reflecting that the high-quality development of the Beijing Stock Exchange will consistently receive policy support. In tandem with the North Exchange 50 Index, the authorization of market data and the development of index funds are progressing smoothly, which will bring additional capital and diversified investors into the market.

This time, our company has successfully been selected as a constituent stock of the “North Exchange 50 Index,” which reflects the capital market’s recognition of our company and serves as a strong incentive for our continued development. All employees are greatly encouraged by this achievement. We will continue to strengthen our scientific research management, accelerate the progress of clinical trials, speed up the construction of our industrialization base, enhance standardized management, promptly disclose information, maintain healthy investor relations, and strive to improve our operational performance. We are committed to delivering outstanding results that will reward our shareholders, benefit society, and establish a positive image for companies listed on the Beijing Stock Exchange.